Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 9:15:1509379.
doi: 10.3389/fimmu.2024.1509379. eCollection 2024.

Editorial: Cross-reactive immunity and COVID-19

Aristo Vojdani  1   2 , Ahmed Yaqinuddin  3 , Alberto Beretta  4 , Pedro A Reche  5
Affiliations
Editorial

Editorial: Cross-reactive immunity and COVID-19

Aristo Vojdani et al. Front Immunol. .
No abstract available

Keywords: COVID-19; SARS-CoV-2; cross-reactivity; long COVID; pre-existing immunity; vaccines.

PubMed Disclaimer

Conflict of interest statement

Author AV was employed by the company Immunosciences Lab., Inc. Author AV was employed by the company Cyrex Labs, LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Potential sources of present immunity shape the response to SARS-CoV-2 and the COVID-19 vaccine; the immune response to SARS-CoV-2 and COVID vaccines can also produce cross-reactive immune responses to other factors.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic Cross-reactive immunity and COVID-19

Similar articles

See all similar articles

References

    1. Agrawal B. Heterologous immunity: role in natural and vaccine-induced resistance to infections. Front Immunol. (2019) 10:2631. doi: 10.3389/fimmu.2019.02631 - DOI - PMC - PubMed
    1. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res. (2017) 2017:2680160. doi: 10.1155/2017/2680160 - DOI - PMC - PubMed
    1. Van Regenmortel MH. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit. (2014) 27:627–39. doi: 10.1002/jmr.v27.11 - DOI - PubMed
    1. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. (2012) 12:669–77. doi: 10.1038/nri3279 - DOI - PMC - PubMed
    1. Ng KW, Faulkner N, Wrobel AG, Gamblin SJ and Kassiotis G. Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. Semin Immunol. (2021) 55:101507. doi: 10.1016/j.smim.2021.101507 - DOI - PMC - PubMed

Publication types

LinkOut - more resources